NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Leukemia Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Acute

ECOG-ACRIN E1910 - "A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults"

CANCER TYPE: Acute
RESEARCH BASE: CTSU E1910
NCT NUMBER: 02003222
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 09/26/2018 (20:46:02)

BRIEF DESCRIPTION

ALL, new dx, B-lineage BCR/ABL negative, age >=30 & <=70, BM & perip blood must be submitted pre-regist; Eval of Blinatumomab.  DCP-001 Eligible






ECOG-ACRIN EA9131 - "A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)"

CANCER TYPE: Acute
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03253848
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 08/16/2018 (20:47:54)

BRIEF DESCRIPTION

To evaluate if the proposed patient care strategy, that includes use of simplified Guidelines along with APL expert support, decreases the one-month induction mortality rate from 30% to under 15%.  DCP-001 Eligible






Chronic

SWOG S1712 - " A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease.

CANCER TYPE: Chronic
RESEARCH BASE: SWOG
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 08/15/2018 (17:22:49)

BRIEF DESCRIPTION

CML w/molecular disease, Dasatinib or Nilotinib +/- Ruxolitinib.  DCP-001 Eligible









  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA